118 related articles for article (PubMed ID: 34091293)
1. Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis.
Liu S; Liu Y; Yang J; Santos TD; Yang L; Li M; Jiang Q; Ma C
Transl Oncol; 2021 Aug; 14(8):101139. PubMed ID: 34091293
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
3. Isotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.
Bouchart C; Engelholm JL; Closset J; Navez J; Loi P; Gökburun Y; De Grez T; Mans L; Hendlisz A; Bali MA; Eisendrath P; Van Gestel D; Hein M; Moretti L; Van Laethem JL
Ther Adv Med Oncol; 2021; 13():17588359211045860. PubMed ID: 34691244
[TBL] [Abstract][Full Text] [Related]
4. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study.
Bordeau K; Michalet M; Keskes A; Valdenaire S; Debuire P; Cantaloube M; Cabaillé M; Portales F; Draghici R; Ychou M; Assenat E; Mazard T; Samalin E; Gauthier L; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612004
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
7. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM
Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.
Michalet M; Bordeau K; Cantaloube M; Valdenaire S; Debuire P; Simeon S; Portales F; Draghici R; Ychou M; Assenat E; Dupuy M; Gourgou S; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
Front Oncol; 2022; 12():842402. PubMed ID: 35356227
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials.
Petrelli F; Comito T; Ghidini A; Torri V; Scorsetti M; Barni S
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):313-322. PubMed ID: 28068239
[TBL] [Abstract][Full Text] [Related]
10. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
11. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer.
Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK
J Gastrointest Oncol; 2022 Feb; 13(1):368-379. PubMed ID: 35284125
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
[TBL] [Abstract][Full Text] [Related]
13. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma.
Chapman BC; Gleisner A; Rigg D; Meguid C; Goodman K; Brauer B; Gajdos C; Schulick RD; Edil BH; McCarter MD
J Surg Oncol; 2018 Apr; 117(5):1073-1083. PubMed ID: 29448308
[TBL] [Abstract][Full Text] [Related]
14. Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study.
Lewis S; Sastri SC; Arya S; Mehta S; Patil P; Shrivastava S; Phurailatpam R; Shrikhande SV; Engineer R
J Gastrointest Oncol; 2019 Jun; 10(3):474-482. PubMed ID: 31183197
[TBL] [Abstract][Full Text] [Related]
15. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy.
Jin WH; Mellon EA; Frakes JM; Murimwa GZ; Hodul PJ; Pimiento JM; Malafa MP; Hoffe SE
J Gastrointest Oncol; 2018 Feb; 9(1):24-34. PubMed ID: 29564168
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma.
Yoo C; Hwang I; Song TJ; Lee SS; Jeong JH; Park DH; Seo DW; Lee SK; Kim MH; Byun JH; Park JH; Hwang DW; Song KB; Lee JH; Lee W; Chang HM; Kim KP; Kim SC; Ryoo BY
Ther Adv Med Oncol; 2020; 12():1758835920953294. PubMed ID: 32983266
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial).
Suker M; Nuyttens JJ; Eskens FALM; Haberkorn BCM; Coene PLO; van der Harst E; Bonsing BA; Vahrmeijer AL; Mieog JSD; Jan Swijnenburg R; Roos D; Koerkamp BG; van Eijck CHJ
EClinicalMedicine; 2019 Dec; 17():100200. PubMed ID: 31891135
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data.
Shouman MA; Fuchs F; Walter F; Corradini S; Westphalen CB; Vornhülz M; Beyer G; Andrade D; Belka C; Niyazi M; Rogowski P
Clin Transl Radiat Oncol; 2024 Mar; 45():100738. PubMed ID: 38370495
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome.
Teriaca MA; Loi M; Suker M; Eskens FALM; van Eijck CHJ; Nuyttens JJ
Radiother Oncol; 2021 Feb; 155():232-236. PubMed ID: 33217500
[TBL] [Abstract][Full Text] [Related]
20. Reirradiation using stereotactic body radiotherapy in the management of recurrent or second primary head and neck cancer: A meta-analysis and systematic review.
Lee J; Kim WC; Yoon WS; Koom WS; Rim CH
Oral Oncol; 2020 Aug; 107():104757. PubMed ID: 32388412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
